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Abstract 
 
Objective: A low circulating level of bilirubin is associated with increased cardiovascular risk.  
As statins can stimulate heme oxygenase-1 (HO-1), which increases bilirubin production, we 
investigated whether statins in routine use increase total bilirubin levels in subjects at high 
cardiovascular risk. 
Methods: Data from 3290 subjects with self-reported history of hypercholesterolemia, 
diabetes, or cardiovascular diseases in the United States National Health and Nutrition 
Examination Survey (NHANES) 1999-2008 were analyzed.   
Results: Subjects taking statins (n=1156) had lower total bilirubin levels than those not 
taking any lipid-lowering medication (n=2134) after adjusting for age, sex, race/ethnicity, 
and survey period (adjusted mean=0.699 vs 0.729 mg/dl respectively, P=0.001).  The 
association remained significant after adjusting for more covariates (P=0.002), but was 
attenuated after further adjusting for glycosylated hemoglobin, insulin resistance index, and 
low-density lipoprotein (LDL) cholesterol (P=0.043).  The use of lovastatin, rosuvastatin, 
and cerivastatin was associated with lower total bilirubin levels in the full adjustment model 
(P<0.05).   
Conclusion: The use of statins was associated unexpectedly with lower total bilirubin levels.  
This could be explained at least partly by the effect of statins on glycemia and LDL 
cholesterol.  Our results do not suggest that the anti-oxidant and anti-inflammatory effects of 
statins are due to HO-1 induction and increased serum bilirubin levels. 
 
Keywords: bilirubin; cardiovascular risk; heme oxygenase; NHANES; statins 
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1. Introduction 
Bilirubin has antioxidant and anti-inflammatory effects [1].  It is the metabolic product of 
heme catabolism and circulates in the blood in either a direct (conjugated) or an indirect 
(unconjugated) form.  Heme oxygenase (HO) is the rate-limiting enzyme in the degradation 
of heme to biliverdin, carbon monoxide, and ferritin.  Biliverdin is then converted to 
bilirubin by the enzyme biliverdin reductase [2].  There are three isoforms of HO, namely, 
HO-1, HO-2, and HO-3 [3].  HO-1 is an inducible enzyme whereas HO-2 and HO-3 are 
constitutively expressed.  Bilirubin can protect lipid from oxidation, and the deletion of 
HO-2 results in greater lipid than protein oxidation [4].  Bilirubin is a protective biomarker 
for cardiovascular risk.  Previous studies have demonstrated an association of lower 
circulating total bilirubin levels with higher risk of the metabolic syndrome [5], coronary 
artery disease [6], peripheral arterial disease (PAD) [7], stroke [8], and other cardiovascular 
diseases (CVDs) [1].  A low circulating level of total bilirubin is also associated with 
increased body mass index (BMI), blood pressure, and insulin resistance [1,5].   
 
HO-1 has been suggested as a promising therapeutic target in vascular diseases [9,10].  The 
increase in HO-1 expression, induced by either pharmacological methods or gene transfer, 
improves vascular dysfunction in animal models of various CVDs including atherosclerosis, 
thrombosis, myocardial infarction, and hypertension [10].  Moreover, HO-1 also plays a role 
in vascular repair by increasing circulating endothelial progenitor cells [11].  Previous 
studies have demonstrated that statins can activate HO-1, an observation that has been 
implicated as contributing to their anti-inflammatory and anti-proliferative effects [12-14].  
Furthermore, the anti-oxidant effect of HO-1 induction by statins has been attributed to the 
reaction products of HO-1, biliverdin, and ferritin [14].  Therefore, statin treatment in 
human subjects with high cardiovascular risk may increase HO-1 activity and hence bilirubin 
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production.  Therefore, we investigated whether statins in routine use could affect total 
bilirubin levels using data from the US National Health and Nutrition Examination Survey 
(NHANES).  This could help to explain whether the anti-oxidative and anti-inflammatory 
effects of statins may be mediated through induction of HO-1 and an increase in serum 
bilirubin levels. 
 
2. Methods 
2.1. Study subjects 
NHANES was conducted by the National Center for Health Statistics of the Centers for 
Disease Control and Prevention to monitor the health and nutritional status of the civilian, 
non-institutionalized US population [15].  Since 1999, NHANES has become a continuous 
cross-sectional survey program and data are released for every two-year cycle.  The detailed 
measurement procedures and protocols are described in its website [15].  All participants 
gave informed consent and the study received approval from the Centers for Disease Control 
and Prevention Institutional Review Board.  In NHANES 1999-2008, after excluding 
pregnant women, there were 23,539 subjects aged ≥20 years who were both interviewed and 
examined in the mobile examination center. 
 
As serum triglycerides and low-density lipoprotein (LDL) cholesterol were measured only in 
subjects who were examined in the morning session and had fasted for 8-24 hours [15], our 
analysis was limited to 9891 subjects.  Among these subjects, information on prescription 
medications for lowering blood lipids was available in 9835 subjects with 3824 of them 
having a self-reported history of hypercholesterolemia, diabetes, or CVDs.  After further 
excluding subjects with abnormal liver function (defined as a serum aspartate 
aminotransferase [AST] or alanine aminotransferase [ALT] >100 U/l, a serum 
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gamma-glutamyltransferase [GGT] >100 U/l, or total bilirubin level >3 mg/dl) [16] or a 
self-reported history of liver diseases, there were 3397 subjects.  A total of 107 subjects 
taking lipid-lowering medications other than statins, such as fibrates, bile acid sequestrants, 
and nicotinic acid were also excluded from the analysis.  Therefore, 3290 subjects were 
included in this analysis. 
 
2.2. Variables of interest 
The usage of lipid lowering medications in the past month was assessed by questionnaires.  
Subjects who reported the use of atorvastatin, simvastatin, pravastatin, lovastatin, 
rosuvastatin, fluvastatin, or cerivastatin were defined as receiving statin treatment, regardless 
of whether the drugs were taken as one combination pill or as two different pills.  Subjects 
with unspecified lipid-lowering medications were excluded from the analysis (n=17).  
Information on race/ethnicity, history of hypercholesterolemia, diabetes, CVDs (heart attack, 
congestive heart failure, coronary heart disease, angina, or stroke) and liver diseases were 
obtained from self-reported questionnaires.  Pregnancy was determined in women by a 
self-reported questionnaire and a urine pregnancy test.  BMI was calculated as weight in 
kilograms divided by the square of height in meters.  Hypertension was defined as blood 
pressure ≥140/90 mmHg or taking anti-hypertensive medications.  Smokers were defined as 
subjects who had smoked ≥100 cigarettes in their lives.  Current and former smokers were 
then classified based on the question, “Do you now smoke cigarettes?”.  Alcohol drinking 
was defined as consumption of any type of alcoholic beverage at least once a week in the past 
one year.   
 
2.3. Laboratory measurement 
The laboratory analytical methods used in NHANES have been described in detail elsewhere 
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[15].  Briefly, serum creatinine, alkaline phosphatase (ALP), ALT, AST, GGT, and total 
bilirubin levels were measured as the routine laboratory blood parameters using an Hitachi 
Model 704 multichannel analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN) in 
1999-2000, a Beckman Synchron LX20 system in 2003-2007 and a Beckman UniCel® 
DxC800 Synchron (Beckman Coulter Inc, Fullerton, CA) in 2008.  In 2001-2002, these 
levels were measured using either an Hitachi Model 704 multichannel analyzer or a Beckman 
Synchron LX20.  The reported values have been adjusted by regression equations to allow 
comparison across the two methods [15].  Correction for serum creatinine data in 1999-2000 
and 2005-2006 according to the NHANES protocol [15] was performed before calculating 
the glomerular filtration rate (GFR).  GFR was estimated from the modified prediction 
equation from the Modification of Diet in Renal Disease study [17].  Total bilirubin levels, 
but not direct or indirect bilirubin levels, were measured in NHANES 1999-2008. 
 
Serum total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides were 
measured with an Hitachi Model 704 multichannel analyzer in 1999-2004, a Roche Hitachi 
717 (Roche Diagnostics, Indianapolis, IN) in 2005, both Roche Hitachi 717 and 912 (Roche 
Diagnostics, Indianapolis, IN) in 2006, and a Roche Modular P chemistry analyzer (Roche 
Diagnostics, Indianapolis, IN) in 2007-2008.  LDL cholesterol was calculated using the 
Friedewald equation.  Fasting glucose was measured by a Cobas Mira Chemistry System 
(Roche Diagnostic Systems, Indianapolis, IN) in 1999-2004, a Roche/Hitachi 911 (Roche 
Diagnostics, Indianapolis, IN) in 2005-2006, and a Roche Modular P Chemistry Analyzer in 
2007-2008.  Fasting insulin was measured using a Pharmacia Insulin RIA kit (Pharmacia 
Diagnostics AB, Uppsala, Sweden) in 1999-2002, a Tosoh AIA-PACK IRI (a two-site 
immunoenzymometric assay) in 2003-2004, and an ELISA kit (Mercodia AB, Uppsala, 
Sweden) in 2005-2008.  Glycosylated hemoglobin (HbA1c) was determined by a Primus 
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CLC330 or a Primus CLC 385 (Primus Corporation, Kansas City, MO) in 1999-2004, a 
Tosoh A1c 2.2 Plus Glycohemoglobin Analyzer (Tosoh Medics Inc, San Francisco, CA) in 
2005-2006, and an A1c G7 HPLC Glycohemoglobin Analyzer (Tosoh Medics Inc, San 
Francisco, CA) in 2007-2008.  Data on fasting glucose, insulin, and HBA1c were adjusted 
using regression equations so that measurements across survey periods could be combined 
[15].  Insulin resistance was assessed by the homeostasis model assessment of insulin 
resistance index (HOMA-IR) [18].  C-reactive protein (CRP) was measured by a Dade 
Behring Nephelometer II Analyzer System (Dade Behring Diagnostics Inc, Somerville, NJ).   
 
2.4. Statistical analysis 
Data analysis was performed using the complex sample function of SPSS version 18.0 (SPSS 
Inc, Chicago, IL).  Data are expressed as mean or percent (SE).  Variables with skewed 
distributions were log-transformed before analysis and are expressed as a geometric mean 
(95% CI).  Fasting sampling weights were used in all analyses to adjust for non-response 
bias and the oversampling of blacks, Mexican Americans, and the elderly among the fasting 
sub-sample in NHANES [15].  Multiple linear regression was used to adjust the association 
for covariates.  Variables were used as covariates in the regression model if they were 
significantly different between subjects with and without statin treatment.  For variables that 
were highly correlated, only one was entered into the regression analysis.  To take account 
for the variations which may be due to changes in measurement sites and methods, survey 
year was included in the regression model as a categorical independent variable.  The P for 
interaction was estimated by including each multiplicative interaction term in the linear 
regression models after adjusting for the main effects of all covariates. 
 
3. Results 
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In this study, there were 2134 (percent [SE] = 66.0 [1.1] %) subjects without taking any 
lipid-lowing medication and 1156 (percent [SE] = 34.0 [1.1] %) subjects taking statins.  
Among 1156 subjects taking statin, 1022 (percent [SE] = 87.2 [1.2] %) subjects took statins 
as the only lipid-lowering medication.  Table 1 shows the clinical characteristics of these 
subjects.  Compared to subjects not on any lipid-lowing medication, those taking statins 
were more likely to be men and non-Hispanic white.  They had higher mean age, BMI, 
HbA1c, fasting glucose, fasting insulin, HOMA-IR, systolic blood pressure, ALT and GGT, 
but lower total cholesterol, LDL cholesterol, GFR, and CRP level.  The percentage of 
former smoking, and prevalence of coronary heart disease, angina, heart attack, any CVD, 
diabetes, hypercholesterolemia and hypertension were all significantly higher in subjects 
taking statins than those without taking any lipid-lowering medication.  Similar results were 
obtained when subjects not on any lipid-lowing medication were compared to subjects taking 
statins as the only lipid-lowering medication, except that the difference in the prevalence of 
any CVD, GFR, and CRP level did not reach statistical significance (Table 1). 
 
As shown in Table 2, although subjects taking statins had a higher unadjusted level of total 
bilirubin than those not taking any lipid-lowering medication, this trend was reversed after 
adjustment for age, sex, race/ethnicity, and survey period (model 1, P=0.001).  In this 
adjustment model, the adjusted mean (SE) of total bilirubin level was 0.729 (0.008) mg/dl in 
subjects not taking any lipid-lowering medication and 0.699 (0.008) mg/dl in subjects taking 
statins (P=0.001).  Further adjustment for BMI, smoking, hypertension, history of any CVD, 
GFR, CRP, ALT, and GGT did not attenuate the association (model 2, P=0.002).  However, 
the association was attenuated after further adjusting for HbA1c, HOMA-IR, and LDL 
cholesterol (models 3 and 4, P=0.020 and 0.043, respectively).  There was no significant 
interaction between statin usage and any of the covariates (P for interaction >0.05).  A 
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similar trend was obtained after exclusion of 134 subjects taking other types of lipid-lowering 
drugs, in which the association was not significant in the full adjustment model (Table 2).   
 
We then investigated whether different types of statins may differ in their effect on total 
bilirubin level.  One subject, who took more than one type of statin (i.e. atorvastatin and 
cerivastatin), was excluded from the analysis.  As shown in Table 3, the use of lovastatin, 
rosuvastatin, and cerivastatin were associated with lower total bilirubin levels in the full 
adjustment model (P=0.001, 0.028, and 0.004 respectively), in which the effect size of 
cerivastatin tended to be the greatest (regression coefficient [SE] = -0.098 [0.033] mg/dl).  
When subjects taking lipid-lowering medications other than statins were excluded, similar 
results were obtained, in which the use of simvastatin was also associated with lower total 
bilirubin level with a borderline significance (regression coefficient [SE] = -0.044 [0.022] 
mg/dl, P=0.046 in full adjustment model).  In a separate analysis, replacement of LDL 
cholesterol with total cholesterol in the regression models as shown in Tables 2 and 3 did not 
affect the results significantly (data not shown). 
 
4. Discussion 
Statins can lower LDL cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase and are used widely to reduce CVD risk [19].  Besides their 
lipid-lowering effect, statins also possess other properties such as the inhibition of 
inflammation and oxidation, and the attenuation of endothelial dysfunction and vascular 
remodeling [19].  The anti-oxidant and anti-inflammatory effects of statins exist even at 
routine clinical dosage, as demonstrated by the reduction of systemic levels of oxidative 
stress markers such as protein-bound nitrotyrosine [20] and inflammatory markers such as 
CRP [21,22].  As statins can stimulate HO-1 and increase the production of bilirubin 
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[12-14,23], we expected that statin usage would be associated with a higher total bilirubin 
level, which may explain part of their anti-oxidant and anti-inflammatory effects.  However, 
in this study, statin usage was unexpectedly associated with a lower total bilirubin level 
among subjects at high cardiovascular risk (i.e. with a self-reported history of diabetes, 
hypercholesterolemia, or CVDs) in NHANES 1999-2008.  Therefore, the anti-oxidant and 
anti-inflammatory effects of statins reflect the activation of antioxidant and anti-inflammatory 
pathways that are independent of HO-1 induction. 
 
Previous cell and animal studies have focused on the effect of statins on HO-1 expression and 
activity.  Lee et al. first reported that simvastatin can activate HO-1 in human and rat aortic 
vascular smooth muscle cells, but not in endothelial cells or macrophages [12].  Ali et al. 
then demonstrated that HO-1 plays a central role in the anti-oxidant properties of atorvastatin 
in human vascular endothelial cells through the generation of biliverdin and ferritin [14].  In 
mice, the plasma total bilirubin level increased after three weeks of treatment with 
rosuvastatin or atorvastatin, without affecting other liver enzyme activities (ALT, AST, ALP, 
and GGT) [23].   
 
The long-term effect of statins on bilirubin levels in humans is not known.  In a randomized 
trial, the use of pravastatin in patients with advanced hepatocellular carcinoma was associated 
with a lower serum total bilirubin level after one year compared to the control group [24].  
However, the sample size of this study was small and the effect of pravastatin on bilirubin 
levels could have been confounded by the presence of chronic liver disease.  The present 
study is therefore the first report showing that statin treatment is associated with a lower total 
bilirubin level in subjects at high cardiovascular risk. 
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A low circulating level of bilirubin is associated with increased cardiovascular risk [1].  For 
example, each 0.1 mg/dl increase in total bilirubin level is associated with 6% and 9% 
decrease in the odds of PAD and stoke, respectively [7,8].  Therefore, the reduced bilirubin 
level in subjects treated with statins could predispose them to higher cardiovascular risk.  As 
statin can stimulate HO-1 activity in cell and animal studies [12-14,23], the mechanism 
underlying the association of statin usage with a lower, rather than a higher, total bilirubin 
level in the present study is not clear.  However, HO-1 can have pro-oxidative effect, in 
addition to its well-studied anti-oxidative effect [25].  Moreover, the effect of statins on in 
vivo HO-1 expression is tissue-specific [13] and thus the circulating level of bilirubin may not 
reflect the local tissue-specific effect of statins on HO-1 induction.  The decrease in total 
bilirubin levels in subjects with statin treatment may probably be due to the inhibition of 
HO-1 activity in some tissues, or increased degradation or excretion of bilirubin by statins.  
Further studies are needed to investigate these speculative mechanisms. 
 
Statins vary in their ability to lower LDL cholesterol and raise HDL cholesterol [26,27].  For 
example, in a recent meta-analysis, rosuvastatin was found to lower LDL cholesterol and 
apolipoprotein B more effectively than atorvastatin and simvastatin at the same dose [26].  
The effect of statins on in vivo HO-1 expression is also statin-specific, with lovastatin having 
a larger effect than simvastatin, atorvastatin, and rosuvastatin in the liver [13].  These 
differential effects of statins on blood lipids and HO-1 expression may contribute to the 
differences in the association of different types of statins with total bilirubin level in this 
study.  Among different types of statins, cerivastatin is associated with the largest decrease 
in total bilirubin level (Table 3). 
 
In the present study, the association of total bilirubin level with the use of statin was 
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attenuated after further adjustment for HbA1c, HOMA-IR, and LDL cholesterol.  Therefore, 
the statin-associated decrease in total bilirubin level could be explained at least partly by the 
effect of statins on glycemia and LDL cholesterol.  As other lipid-lowering medications may 
have the possibility to affect HO-1 activity and bilirubin production, subjects taking other 
concomitant types of lipid-lowering medications such as fibrates, bile acid sequestrants, and 
nicotinic acid were excluded in a separate analysis and similar results were still observed in 
this study. 
 
Despite the adverse effect on total bilirubin level, statins can lower LDL cholesterol and 
reduce CVD risk [21,22,28,29].  These beneficial effects of statins overweigh their small but 
negative effects on total bilirubin level.  In fact, there is a residual cardiovascular risk in 
subjects treated with statins, which could be contributed by the low HDL cholesterol [29].  
Whether the reduced total bilirubin level in subjects treated with statins could contribute to 
this residual risk remains unknown and needs to be further investigated. 
 
Our study has some limitations.  There is a lack of data on the circulating level of HO-1.  
HO-1 levels are elevated in subjects with chronic diseases such as type 2 diabetes [30], 
probably as a protective mechanism against oxidative stress and inflammation.  Another 
limitation is the small sample size in NHANES, which limits the power to perform sub-group 
analysis.  However, our study has the advantage of using data from NHANES with good 
sampling design, quality control, and nationally representative estimates.  As different types 
of statins show differential effects in the association with total bilirubin levels (Table 3), the 
mixed analysis in all statin group (Table 2) might have influenced the result.  A major 
limitation of this study is that subjects treated with statins have a high cardiovascular risk 
profile.  Due to the cross-sectional nature of the NHANES survey, it is difficult to establish 
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the causal and temporal relationship between statin therapy and total bilirubin levels.  
Therefore, future studies of bilirubin levels before and after statin treatment will be of crucial 
importance in order to investigate the nature of such relationships. 
 
5. Conclusion 
We found an unexpected association of statin usage with lower total bilirubin level in 
subjects at high cardiovascular risk in NHANES 1999-2008.  Our results do not suggest that 
statins in routine use exert anti-oxidative and anti-inflammatory effects by inducing HO-1 
and increasing serum bilirubin levels.   
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Table 1. Clinical characteristics among subjects in NHANES 1999-2008. 
Characteristics No lipid-lowering 
medication 
Taking statins 
  All subjects  Subjects with statins 
as the only 
lipid-lowering 
medication† 
n 2134 1156 1022 
Age, y 53.0 (0.5) 62.2 (0.5)║ 62.4 (0.5)║ 
Women, % 54.6 (1.5) 48.2 (1.6)║ 49.3 (1.7)║ 
BMI, kg/m2  29.3 (0.2) 29.7 (0.2)§ 29.7 (0.2)§ 
Race/ethnicity, %    
Non-Hispanic white 73.3 (1.7) 81.2 (1.7)§ 80.6 (1.9)‡ 
Non-Hispanic black 11.2 (1.1) 7.5 (1.0)‡ 8.1 (1.1) 
Mexican American 6.1 (0.8) 3.3 (0.5)║ 3.2 (0.5)§ 
Others 9.5 (1.1) 8.1 (1.3) 8.0 (1.3) 
Smoking, %    
Never  47.9 (1.4) 43.1 (1.6) 44.1 (1.7) 
Former 30.9 (1.1) 41.9 (1.4)‡ 41.7 (1.6)‡ 
Current 21.1 (1.2) 15.1 (1.4) 14.2 (1.4) 
Alcohol drinking, % 30.3 (1.4) 29.4 (2.1) 28.5 (2.3) 
History of CVD, %    
Congestive heart 
failure 
5.0 (0.6) 7.3 (0.9) 6.9 (0.9) 
Coronary heart 4.5 (0.5) 19.7 (1.2)║ 16.5 (1.3)║ 
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disease 
Angina 4.6 (0.6) 12.8 (1.1)║ 11.1 (1.1)║ 
Heart attack 6.1 (0.6) 15.7 (1.1)║ 14.1 (1.2)§ 
Stroke 6.6 (0.7) 9.1 (0.9) 9.3 (1.0) 
Any of the above 17.4 (1.2) 31.8 (1.6)§ 28.7 (1.9) 
HbA1c, %* 5.61 (5.55-5.67) 5.89 (5.82-5.97)║ 5.88 (5.80-5.97)║ 
Fasting glucose, 
mmol/l* 
6.02 (5.95-6.10) 6.32 (6.22-6.42)§ 6.34 (6.23-6.45)║ 
Fasting insulin, mU/l* 8.3 (8.0-8.7) 9.6 (9.1-10.1)║ 9.4 (8.8-9.9)║ 
HOMA-IR* 2.23 (2.12-2.34) 2.69 (2.53-2.86)║ 2.64 (2.47-2.82)║ 
Diabetes, % 18.2 (1.1) 23.6 (1.6)§ 23.4 (1.7)‡ 
Total cholesterol, 
mmol/l 
5.75 (0.03) 4.83 (0.04)║ 4.86 (0.05)║ 
HDL cholesterol, 
mmol/l 
1.35 (0.01) 1.34 (0.01) 1.35 (0.01) 
LDL cholesterol, 
mmol/l 
3.56 (0.03) 2.65 (0.03)║ 2.69 (0.04)║ 
Triglycerides, 
mmol/l* 
1.60 (1.55-1.65) 1.60 (1.54-1.67) 1.60 (1.54-1.67) 
Hypercholesterolemia, 
% 
79.7 (1.3) 91.4 (1.0)║ 91.4 (1.1)║ 
SBP, mmHg 125.9 (0.5) 128.1 (0.8)‡ 128.5 (0.7) 
DBP, mmHg 72.1 (0.4) 68.3 (0.6) 68.6 (0.6) 
Hypertension, % 39.4 (1.4) 65.9 (1.8)║ 65.9 (1.8)║ 
GFR, ml/min/1.73m2 83.8 (0.7) 75.0 (0.9)‡ 75.3 (0.9) 
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CRP, mg/dl* 0.25 (0.23-0.27) 0.21 (0.19-0.24)‡ 0.22 (0.20-0.25) 
ALP, U/l* 68.0 (66.7-69.3) 68.3 (66.8-69.8) 68.7 (67.2-70.4) 
ALT, U/l* 22.3 (21.8-22.8) 22.8 (22.3-23.4)‡ 22.6 (22.0-23.2)‡ 
AST, U/l* 22.6 (22.2-22.9) 23.8 (23.4-24.2) 23.5 (23.1-24.0) 
GGT, U/l* 22.8 (22.1-23.5) 24.2 (23.3-25.1)‡ 24.3 (23.4-25.3)§ 
Data are expressed as mean or percent (SE), or geometric mean (95% CI) unless otherwise 
noted. 
*Data were log-transformed before analysis. 
†Defined as subjects not taking other types of lipid-lowering medications (such as fibrates, 
bile acid sequestrants, and nicotinic acid) concomitantly. 
‡P<0.05, §P<0.01, and ║P<0.001 for comparison between subjects without any medication 
and those taking statins after adjusting for age, sex, race/ethnicity (non-Hispanic white, 
non-Hispanic black, Mexican Americans, and others), and survey period (1999-2000, 
2001-2002, 2003-2004, 2005-2006, and 2007-2008), where appropriate. 
SBP, systolic blood pressure; DBP, diastolic blood pressure. 
 
20 
 
Table 2.  Association of total bilirubin level with the use of statins in NHANES 1999-2008. 
 Unadjusted model Model 1 Model 2 Model 3 Model 4 
All subjects 
Total bilirubin level, mg/dl      
No medication (n=2134) 0.738 (0.009) 0.729 (0.008) 0.718 (0.009) 0.721 (0.009) 0.724 (0.010) 
Statins (n=1156) 0.762 (0.008) 0.699 (0.008) 0.688 (0.009) 0.698 (0.010) 0.698 (0.012) 
Regression coefficient (SE), mg/dl* 0.024 (0.010) -0.030 (0.009) -0.029 (0.009) -0.023 (0.010) -0.026 (0.013) 
P  0.017 0.001 0.002 0.020 0.043 
      
Subjects with statins as the only lipid-lowering medication 
Total bilirubin level, mg/dl      
No medication (n=2134) 0.74 (0.01) 0.730 (0.008) 0.718 (0.009) 0.721 (0.009) 0.724 (0.009) 
Statins (n=1022) 0.76 (0.01) 0.703 (0.010) 0.688 (0.011) 0.697 (0.011) 0.700 (0.014) 
Regression coefficient (SE), mg/dl* 0.019 (0.010) -0.027 (0.010) -0.030 (0.010) -0.024 (0.011) -0.024 (0.013) 
P  0.068 0.010 0.006 0.027 0.072 
Total bilirubin level is expressed as mean (SE). 
Model 1: Adjusted for age, sex, race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican Americans, and others), and survey period 
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(1999-2000, 2001-2002, 2003-2004, 2005-2006, and 2007-2008). 
Model 2: Further adjusted for BMI, smoking (current, former, and never), hypertension, history of any CVD (no and yes), GFR, CRP 
(log-transformed), ALT (log-transformed), and GGT (log-transformed). 
Model 3: Further adjusted for HbA1c (log-transformed) and HOMA-IR (log-transformed). 
Model 4: Further adjusted for LDL cholesterol. 
*Subjects not taking any lipid-lowering medication as the referent group. 
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Table 3.  Association of total bilirubin level with the use of different types of statins in NHANES 1999-2008. 
 n % (SE) Model 1 Model 2 
   Adjusted total 
bilirubin level, 
mg/dl 
Regression 
coefficient (SE), 
mg/dl 
P Adjusted total 
bilirubin level, 
mg/dl 
Regression 
coefficient (SE), 
mg/dl 
P 
All subjects 
No lipid-lowering medication 2134 66.1 (1.1) 0.729 (0.008) referent - 0.724 (0.010) referent - 
Atorvastatin 482 14.6 (0.8) 0.717 (0.013) -0.012 (0.012) 0.322 0.714 (0.016) -0.010 (0.015) 0.518 
Simvastatin 391 11.0 (0.7) 0.694 (0.015) -0.035 (0.016) 0.033 0.689 (0.019) -0.034 (0.020) 0.087 
Pravastatin 105 3.0 (0.4) 0.718 (0.022) -0.011 (0.024) 0.645 0.718 (0.023) -0.006 (0.025) 0.819 
Lovastatin 94 2.5 (0.3) 0.624 (0.024) -0.105 (0.025) <0.001 0.632 (0.026) -0.092 (0.027) 0.001 
Rosuvastatin 43 1.5 (0.3) 0.617 (0.036) -0.112 (0.036) 0.002 0.652 (0.032) -0.072 (0.032) 0.028 
Fluvastatin 29 0.9 (0.2) 0.719 (0.047) -0.010 (0.047) 0.836 0.732 (0.045) 0.008 (0.046) 0.857 
Cerivastatin 12 0.5 (0.2)* 0.658 (0.033) -0.071 (0.034) 0.042 0.625 (0.031) -0.098 (0.033) 0.004 
Overall trend - - - - 0.001 - - 0.005 
         
Subjects with statins as the only lipid-lowering medication 
23 
 
No lipid-lowering medication 2134 69.1 (1.0) 0.730 (0.009) referent - 0.724 (0.010) referent - 
Atorvastatin 444 14.1 (0.8) 0.726 (0.015) -0.004 (0.013) 0.766 0.720 (0.018) -0.004 (0.016) 0.823 
Simvastatin 322 9.1 (0.6) 0.685 (0.018) -0.044 (0.019) 0.024 0.680 (0.021) -0.044 (0.022) 0.046 
Pravastatin 94 2.7 (0.3) 0.728 (0.023) -0.002 (0.025) 0.950 0.725 (0.023) 0.001 (0.026) 0.958 
Lovastatin 88 2.5 (0.3) 0.628 (0.024) -0.102 (0.025) <0.001 0.636 (0.026) -0.088 (0.027) 0.002 
Rosuvastatin 37 1.3 (0.3) 0.619 (0.032) -0.111 (0.032) 0.001 0.645 (0.032) -0.079 (0.031) 0.014 
Fluvastatin 25 0.7 (0.2) 0.761 (0.045) 0.032 (0.046) 0.491 0.766 (0.052) 0.042 (0.052) 0.427 
Cerivastatin 11 0.5 (0.2)* 0.661 (0.035) -0.069 (0.036) 0.061 0.628 (0.031) -0.096 (0.033) 0.005 
Overall trend -  - - 0.001 - - 0.005 
Total bilirubin level is expressed as mean (SE). 
Model 1: Adjusted for age, sex, race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican Americans, and others), and survey period 
(1999-2000, 2001-2002, 2003-2004, 2005-2006, and 2007-2008). 
Model 2: Further adjusted for BMI, smoking (current, former, and never), hypertension, history of any CVD (no and yes), GFR, CRP 
(log-transformed), ALT (log-transformed), GGT (log-transformed), HbA1c (log-transformed), HOMA-IR (log-transformed), and LDL cholesterol. 
*Estimate was unreliable due to coefficient of variation >0.30. 
 
